Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

TAK-733 was identified as a potential treatment for a hereditary tumor syndrome using Recursion’s approach to creating cellular models of diseases where genes are inactive.

For building a pharma company that uses AI plus tiny snapshots to find treatments that humans would miss, Chris Gibson is one of Fast Company's Most Creative People in Business.

Recursion, a biotech company making new drugs using AI technology, just closed a $121 million Series C round with investors like the venture-capital firm Menlo Ventures.; Around the pharmaceutical ...

Recursion Pharmaceuticals today announced its $12.9 million Series A round of funding, ... Recursion Pharmaceuticals Raises $13M to Discover New Drugs Using Artificial Intelligence.